<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00861640</url>
  </required_header>
  <id_info>
    <org_study_id>KMUH-IRB-970338</org_study_id>
    <nct_id>NCT00861640</nct_id>
  </id_info>
  <brief_title>Comparison of Oral Rabeprazole vs. iv Omeprazole in Mild to Moderate Nonvariceal Upper Gastrointestinal Bleeding</brief_title>
  <official_title>The Comparison of Oral Rabeprazole vs. Intravenous Omeprazole in the Treatment of Patients With Mild to Moderate Nonvariceal Upper Gastrointestinal Bleeding</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaohsiung Medical University Chung-Ho Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kaohsiung Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kaohsiung Medical University Chung-Ho Memorial Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Introduction: Proton pump inhibitor (PPI) is the drug of choice used in patients with&#xD;
      non-variceal upper gastrointestinal tract bleeding (UGIB). Intravenous (IV) PPI is more&#xD;
      commonly used than oral form when overt bleeding occurs. Previous study has revealed that&#xD;
      oral rabeprazole and IV omeprazole achieved similar intragastric pH elevation. It's probable&#xD;
      that oral form and IV PPI provide equal efficacy in treating mild to moderate UGIB patients.&#xD;
&#xD;
      Aim: This study aims to compare the effect of three-day oral rabeprazole and iv omeprazole on&#xD;
      bleeding control in patients with mild to moderate non-variceal UGIB.&#xD;
&#xD;
      Patients and methods: All patients presented with black to tarry stool passage or hematemesis&#xD;
      and visited our ER will be evaluated to recruit into this study. They will receive regular&#xD;
      vital sign monitoring, laboratory study and nasogastric tube insertion with gastric fluid&#xD;
      aspiration. Esophagogastroendoscopy and hemostatic procedure if need will be performed within&#xD;
      12 hours. Those confirmed to have non-variceal UGIB, stable vital signs and agree to&#xD;
      participate into this study will be randomized into two groups receiving either oral&#xD;
      rabeprazole (20mg bid) or iv omeprazole (40mg qd) for three days. The presence of recurrent&#xD;
      bleeding within three days, in-hospital complication and duration of hospital stay will be&#xD;
      recorded and analyzed.&#xD;
&#xD;
      Expected results: At the end of this study, we will be able to determine whether patients&#xD;
      treated with oral rabeprazole and iv omeprazole have similar re-bleeding or complication&#xD;
      rates and hospitalization days.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Proton pump inhibitor (PPI) is the drug of choice used in patients with non-variceal upper&#xD;
      gastrointestinal tract bleeding (UGIB). Intravenous (IV) PPI is more commonly used than oral&#xD;
      form when overt bleeding occurs. Previous study has revealed that oral rabeprazole and IV&#xD;
      omeprazole achieved similar intragastric pH elevation. It's probable that oral form and IV&#xD;
      PPI provide equal efficacy in treating mild to moderate UGIB patients.&#xD;
&#xD;
      This study aims to compare the effect of three-day oral rabeprazole and iv omeprazole on&#xD;
      bleeding control in patients with mild to moderate non-variceal UGIB. The expected numbers of&#xD;
      intravenous and oral PPI were 100 respectively.&#xD;
&#xD;
      All patients presented with black to tarry stool passage or hematemesis and visited our ER&#xD;
      will be evaluated to recruit into this study. They will receive regular vital sign&#xD;
      monitoring, laboratory study and nasogastric tube insertion with gastric fluid aspiration.&#xD;
      Esophagogastroendoscopy and hemostatic procedure if need will be performed within 12 hours.&#xD;
      Those confirmed to have non-variceal UGIB, stable vital signs and agree to participate into&#xD;
      this study will be randomized into two groups receiving either oral rabeprazole (20mg bid) or&#xD;
      iv omeprazole (40mg qd) for three days. The presence of recurrent bleeding within three days,&#xD;
      in-hospital complication and duration of hospital stay will be recorded and analyzed.&#xD;
&#xD;
      At the end of this study, we will be able to determine whether patients treated with oral&#xD;
      rabeprazole and iv pantoprazole have similar re-bleeding or complication rates and&#xD;
      hospitalization days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2009</start_date>
  <completion_date type="Anticipated">April 2010</completion_date>
  <primary_completion_date type="Anticipated">March 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>This study aims to compare the effect of three-day oral rabeprazole and iv omeprazole on bleeding control in patients with mild to moderate non-variceal UGIB.</measure>
    <time_frame>one year later</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Nonvariceal Upper Gastrointestinal Bleeding</condition>
  <arm_group>
    <arm_group_label>Intravenous Omeprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 cases of Intravenous Omeprazole</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral Rabeprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 cases of oral rabeprazole</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous Omeprazole</intervention_name>
    <description>Intravenous Omeprazole 1amp qd (every day)</description>
    <arm_group_label>Intravenous Omeprazole</arm_group_label>
    <other_name>iv losec</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Rabeprazole</intervention_name>
    <description>Oral Rabeprazole 1 bid</description>
    <arm_group_label>Oral Rabeprazole</arm_group_label>
    <other_name>pariet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  moderate to mild upper gastrointestinal peptic ulcer bleeding&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  shock&#xD;
&#xD;
          -  liver cirrhosis&#xD;
&#xD;
          -  uremia&#xD;
&#xD;
          -  severe UGI bleeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chien-Yu Lu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kaohsiung Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chien-Yu Lu, MD</last_name>
    <phone>886-7-3121101</phone>
    <phone_ext>7451</phone_ext>
    <email>dr820188@pchome.com.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kaohsiung Medical University Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chien-Yu Lu, MD</last_name>
      <phone>886-7-3121101</phone>
      <phone_ext>7451</phone_ext>
      <email>dr820188@pchome.com.tw</email>
    </contact>
    <investigator>
      <last_name>Chien-Yu Lu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <link>
    <url>http://www.kmuh.org.tw</url>
    <description>Kaohsiung Medical University Hospital</description>
  </link>
  <verification_date>July 2009</verification_date>
  <study_first_submitted>March 11, 2009</study_first_submitted>
  <study_first_submitted_qc>March 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2009</study_first_posted>
  <last_update_submitted>July 14, 2009</last_update_submitted>
  <last_update_submitted_qc>July 14, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 15, 2009</last_update_posted>
  <responsible_party>
    <name_title>Chien-Yu Lu</name_title>
    <organization>Kaohsiung Medicial University Hospital</organization>
  </responsible_party>
  <keyword>rabeprazole</keyword>
  <keyword>omeprazole</keyword>
  <keyword>upper gastrointestinal bleeding</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omeprazole</mesh_term>
    <mesh_term>Rabeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

